Mizuho cuts Neuropace target price to $12 from $22
NPCE•Mizuho cut its target price for Neuropace to $12 from $22.
Related News

Woori Financial Group's separate total assets rise to KRW 28.77 trillion at end-September
WF•

Vylor Inc. price objective raised to $80 from $78
VYLR•

Blackstone Digital Infrastructure Trust reports Q3 2026 net income of $15.6 million
BXDC•

Agomab Therapeutics director David R. Epstein reports $88,679.20 share purchase
AGMB•

Colgate-Palmolive announces dividend of R$ 0.28194187734 per unit
CL•